---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-110767"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:25:27.690528+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Trevi gains FDA alignment on Phase 3 IPF-cough program; cash $188.3M

## Summary
- FDA alignment on Phase 3 program for IPF-related chronic cough; first Phase 3 trial to start Q2 2026.
- Cash, cash equivalents $188.3M at year-end 2025; expected runway into 2028.
- Q4 2025 net loss $8.3M vs $11.4M in Q4 2024; FY2025 net loss $42.8M.
- R&D expenses Q4 $6.2M down from $9.3M; G&A $4.0M up from $2.9M.
- Plan to initiate Phase 2b trial for refractory chronic cough in Q2 2026.

## SEC filing metadata
- accession: 0001193125-26-110767
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312526110767/0001193125-26-110767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312526110767/trvi-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-110767
- JSON: https://secwatch.observer/filing/0001193125-26-110767.json
- Plain text: https://secwatch.observer/filing/0001193125-26-110767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.